AR108101A1 - Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 - Google Patents
Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119Info
- Publication number
- AR108101A1 AR108101A1 ARP170100901A ARP170100901A AR108101A1 AR 108101 A1 AR108101 A1 AR 108101A1 AR P170100901 A ARP170100901 A AR P170100901A AR P170100901 A ARP170100901 A AR P170100901A AR 108101 A1 AR108101 A1 AR 108101A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- gpr119
- formula
- affections
- treat diseases
- Prior art date
Links
- AJJISMLYIMQAKP-OAHLLOKOSA-N 5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical class CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 AJJISMLYIMQAKP-OAHLLOKOSA-N 0.000 title 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 title 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229940100607 GPR119 agonist Drugs 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos de fórmula (1) como agonistas de GPR119, composiciones que contienen dichos compuestos y método de preparación de las mismas. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), en donde, X¹, X², X³ y X⁴ son cada uno independientemente N, O, S o CH; Y se selecciona a partir de H, OH, halógeno, C₁₋₆ alquilo, C₁₋₆ alcoxi, -(CH)ₙ, amino,-CO, -CONH, -NH(alquilo), -N(alquilo)₂, -NH-aralquilo, -OCH(CH₃); n es 0, 1, 2 ó 3; ⁻ ⁻ ⁻ ⁻ ⁻ es independientemente ya sea un enlace simple o un enlace doble, siempre que enlaces dobles adyacentes (=C=) no estén permitidos; R¹ se selecciona a partir de los restos del grupo de fórmulas (2); R² se selecciona a partir de los restos del grupo de fórmulas (3); R³ se selecciona a partir de H, OH, halógeno, alquilo C₁₋₆, alcoxi C₁₋₆, -(CH)ₙ, amino, -CO, -CONH, -NH(alquilo), -N(alquilo)₂, -NH-aralquilo, -CF₃, -OCH(CH₃), un resto de fórmula (4), un resto de fórmula (5); y sales, hidratos y estereoisómeros farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611012425 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108101A1 true AR108101A1 (es) | 2018-07-18 |
Family
ID=58794109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100901A AR108101A1 (es) | 2016-04-08 | 2017-04-07 | Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10526345B2 (es) |
| EP (1) | EP3440087B1 (es) |
| JP (1) | JP6831450B2 (es) |
| CN (1) | CN109415381B (es) |
| AR (1) | AR108101A1 (es) |
| AU (2) | AU2017246996B2 (es) |
| CA (1) | CA3020478C (es) |
| ES (1) | ES2926625T3 (es) |
| MX (1) | MX388682B (es) |
| NZ (2) | NZ746954A (es) |
| RU (1) | RU2749111C2 (es) |
| TW (1) | TWI657091B (es) |
| WO (1) | WO2017175068A1 (es) |
| ZA (1) | ZA201807350B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201800367A1 (ru) | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
| US10208030B2 (en) * | 2016-04-08 | 2019-02-19 | Mankind Pharma Ltd. | GPR119 agonist compounds |
| KR20200033249A (ko) | 2017-06-05 | 2020-03-27 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| US11395822B2 (en) | 2017-06-28 | 2022-07-26 | Ptc Therapeutics, Inc. | Methods for treating Huntington's disease |
| CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| US12103926B2 (en) | 2018-03-27 | 2024-10-01 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| BR112020026545A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington |
| EA202092899A1 (ru) * | 2018-06-27 | 2021-05-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Гетероарильные соединения для лечения болезни гентингтона |
| US12415816B2 (en) | 2018-11-07 | 2025-09-16 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| CN112955448B (zh) * | 2019-01-31 | 2023-02-03 | 中国医药研究开发中心有限公司 | 芳环或芳杂环类化合物及其制备方法和医药用途 |
| BR112022017039A2 (pt) | 2020-02-28 | 2022-11-16 | Kallyope Inc | Agonistas de gpr40 |
| US20230322754A1 (en) * | 2020-04-28 | 2023-10-12 | Kymera Therapeutics, Inc. | Irak inhibitors and uses thereof |
| EP4146639A1 (en) | 2020-05-06 | 2023-03-15 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| WO2023009712A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Heteroaryloxy thiazolo azines as jak2 inhibitors |
| JP7782035B2 (ja) | 2021-11-09 | 2025-12-08 | エイジャックス セラピューティクス， インコーポレイテッド | Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| IL291418B2 (en) | 2022-03-16 | 2024-05-01 | Anima Biotech Inc | Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment |
| US12102693B1 (en) | 2023-08-25 | 2024-10-01 | Nanomedtrix, Llc | Pharmaceutical composition with nanoparticle-based drug delivery combined with non-invasive radiographic monitoring model |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1340697A (en) * | 1920-02-24 | 1920-05-18 | Austin Herbert | Road-wheel of the sheet-metal type |
| MY103766A (en) | 1987-09-02 | 1993-09-30 | Smithkline Beckman Corp | Pyrrolo[1,2-a]imidazole and imidazo[1,2-a] pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
| JPH11502503A (ja) | 1994-12-21 | 1999-03-02 | ザ ダウ ケミカル カンパニー | 置換チアジアゾール類、それらを含有する組成物並びに抗微生物剤及び海産生物による汚染に対する防止剤としてのそれらの使用 |
| DK2280704T3 (en) | 2008-03-31 | 2015-06-29 | Cymabay Therapeutics Inc | Oxymethylenarylforbindelser and uses thereof |
| US20110160222A1 (en) | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
| US8940716B2 (en) | 2010-05-06 | 2015-01-27 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as GPR119 modulators |
| UY33805A (es) * | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| AU2012208530A1 (en) | 2011-01-21 | 2013-07-11 | Boehringer Ingelheim International Gmbh | Fused dihydrofurans as GPR119 modulators for the treatment of diabetes, obesity and related disorders |
| PH12013501686A1 (en) * | 2011-02-25 | 2017-10-25 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| EA031618B1 (ru) * | 2011-06-09 | 2019-01-31 | Ризен Фармасьютикалз Са | Соединения-модуляторы gpr-119 |
| CN102898400B (zh) | 2011-07-28 | 2015-04-29 | 北京韩美药品有限公司 | Gpr119激动剂及其应用 |
| US8853239B2 (en) * | 2011-12-09 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| DK2858986T3 (da) | 2012-06-12 | 2019-11-25 | Chong Kun Dang Pharmaceutical Corp | Piperidinderivater som gpr119-agonister |
-
2017
- 2017-04-04 US US15/478,883 patent/US10526345B2/en active Active
- 2017-04-05 NZ NZ746954A patent/NZ746954A/en unknown
- 2017-04-05 JP JP2019503800A patent/JP6831450B2/ja active Active
- 2017-04-05 EP EP17726352.2A patent/EP3440087B1/en active Active
- 2017-04-05 ES ES17726352T patent/ES2926625T3/es active Active
- 2017-04-05 WO PCT/IB2017/000471 patent/WO2017175068A1/en not_active Ceased
- 2017-04-05 RU RU2018138050A patent/RU2749111C2/ru active
- 2017-04-05 AU AU2017246996A patent/AU2017246996B2/en active Active
- 2017-04-05 NZ NZ763098A patent/NZ763098A/en unknown
- 2017-04-05 CN CN201780022556.2A patent/CN109415381B/zh active Active
- 2017-04-05 CA CA3020478A patent/CA3020478C/en active Active
- 2017-04-05 MX MX2018012087A patent/MX388682B/es unknown
- 2017-04-07 TW TW106111799A patent/TWI657091B/zh active
- 2017-04-07 AR ARP170100901A patent/AR108101A1/es active IP Right Grant
-
2018
- 2018-11-02 ZA ZA2018/07350A patent/ZA201807350B/en unknown
-
2019
- 2019-10-14 US US16/601,109 patent/US10919915B2/en active Active
-
2020
- 2020-02-27 AU AU2020201450A patent/AU2020201450B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6831450B2 (ja) | 2021-02-17 |
| TWI657091B (zh) | 2019-04-21 |
| US10526345B2 (en) | 2020-01-07 |
| RU2018138050A (ru) | 2020-05-12 |
| AU2020201450B2 (en) | 2021-07-01 |
| CN109415381A (zh) | 2019-03-01 |
| CA3020478A1 (en) | 2017-10-12 |
| ZA201807350B (en) | 2019-08-28 |
| MX388682B (es) | 2025-03-20 |
| ES2926625T3 (es) | 2022-10-27 |
| RU2749111C2 (ru) | 2021-06-04 |
| WO2017175068A8 (en) | 2018-05-11 |
| US20170291910A1 (en) | 2017-10-12 |
| CA3020478C (en) | 2021-07-20 |
| AU2020201450A1 (en) | 2020-03-19 |
| CN109415381B (zh) | 2022-03-25 |
| EP3440087B1 (en) | 2022-08-10 |
| BR112018070727A2 (pt) | 2019-03-06 |
| WO2017175068A1 (en) | 2017-10-12 |
| US10919915B2 (en) | 2021-02-16 |
| NZ746954A (en) | 2020-04-24 |
| US20200040006A1 (en) | 2020-02-06 |
| MX2018012087A (es) | 2019-06-12 |
| EP3440087A1 (en) | 2019-02-13 |
| RU2018138050A3 (es) | 2020-05-12 |
| JP2019513834A (ja) | 2019-05-30 |
| TW201741318A (zh) | 2017-12-01 |
| AU2017246996A1 (en) | 2018-11-01 |
| AU2017246996B2 (en) | 2019-11-28 |
| NZ763098A (en) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108101A1 (es) | Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 | |
| AR108102A1 (es) | Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 | |
| AR093759A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| CL2021001098A1 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| MX2020000404A (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| AR090589A1 (es) | INHIBIDORES DE b-LACTAMASA ISOXAZOL | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| UY36207A (es) | Inhibidores de la syk | |
| AR085958A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del cns y cancer | |
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
| DOP2014000178A (es) | Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| AR097963A1 (es) | Antagonistas de receptor ep3 de prostaglandina | |
| EA201591645A1 (ru) | Hантагонисты, имеющие феноксипиперидиновое ядро в структуре | |
| ECSP088257A (es) | Derivados de amida | |
| PE20140629A1 (es) | Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos | |
| AR071111A1 (es) | Derivados de amidas del acido 3-trifluorometil-pirazin-2-carboxilico como agentes para aumentar el hdl-colesterol, composiciones farmaceuticas y un metodo para su preparacion. | |
| EA201491878A8 (ru) | Замещенные ксантиновые производные | |
| AR085905A1 (es) | Una combinacion farmaceutica sinergistica para el tratamiento del cancer de pancreas | |
| AR093168A1 (es) | COMPUESTOS DE OXAZOLIDINONA COMO INHIBIDORES DEL CANAL KCa3.1 | |
| AR097890A1 (es) | Compuestos de urea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |